Clinicopathological features and long-term outcomes of pleural solitary fibrous tumors


Köse E. E., Kosif A., Metin S. K., AĞCA M., Alpay A. L., BAYSUNGUR S. V.

Nagoya Journal of Medical Science, cilt.88, sa.3, ss.465-476, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 88 Sayı: 3
  • Basım Tarihi: 2026
  • Doi Numarası: 10.18999/nagjms.88.3.465
  • Dergi Adı: Nagoya Journal of Medical Science
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.465-476
  • Anahtar Kelimeler: pleural solitary fibrous tumors, malignancy, SUVmax, Ki-67 index, survival
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Pleural solitary fibrous tumors (PSFT) are rare mesenchymal neoplasms with heterogeneous biological behavior. Although most tumors are histologically benign, recurrence and distant metastasis may occur, complicating prognostic stratification. This retrospective study evaluated the clinicopathological characteristics and long-term outcomes of 47 patients who underwent surgical resection for PSFT between January 2008 and June 2023, with particular focus on tumor size, positron emission tomography–computed tomography (PET-CT)–derived maximum standardized uptake value (SUVmax), and Ki-67 proliferation index. The mean tumor diameter was 8.4 cm, with 31.9% of the cases presenting a tumor size of ≥10 cm. Malignant histology was identified in 14 patients (29.7%). PET-CT was available in 28 patients; SUVmax ≥2.5 was observed in all malignant tumors and in 35.0% of benign tumors (p = 0.004). Ki-67 data were available in 18 patients, and Ki-67 ≥10% was significantly more frequent in malignant tumors than in benign tumors (p = 0.005). Complete R0 resection was achieved in all patients. The 5-year overall survival rate was 89.3%, with lower survival in malignant tumors compared with benign tumors (78.6% vs 93.9%). Local recurrence was observed in one patient with benign histology, while brain metastasis occurred in a patient with malignant histology. These findings suggest that the clinical behavior of PSFT cannot be reliably predicted based solely on histopathological features or tumor size. Instead, they indicate that metabolic and proliferative markers may provide valuable prognostic insights, highlighting the necessity for long-term, risk-stratified follow-up for all patients.